Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aaron M Goodman

Showing results (61-70 of 79) with videos related to

Pageof 8
Sort By:
Blood Cancer Journal|November 15, 2022
Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015-2020Oliver Van Oekelen, Nicole Birrer, William Wesson, et al.
JAMA Oncology|June 15, 2018
Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid TumorsAaron M Goodman, David Piccioni, Shumei Kato, et al.
Blood Advances|March 1, 2023
Successful treatment of non-Langerhans cell histiocytosis with the MEK inhibitor trametinib: a multicenter analysisAshley Aaroe, Razelle Kurzrock, Gaurav Goyal, et al.
JAMA Internal Medicine|April 28, 2023
Comparing Physician and Artificial Intelligence Chatbot Responses to Patient Questions Posted to a Public Social Media ForumJohn W Ayers, Adam Poliak, Mark Dredze, et al.
Journal of Cancer Policy|December 7, 2023
Use of subjective minimizing language at hematology and oncology conferences: A systematic reviewAbdel-Azez Abusamak, Mohammad Abusamak, Mohammed Al-Abbadi, et al.
Molecular Cancer Therapeutics|December 8, 2018
Genome-Wide Sequencing of Cell-Free DNA Identifies Copy-Number Alterations That Can Be Used for Monitoring Response to Immunotherapy in Cancer PatientsTaylor J Jensen, Aaron M Goodman, Shumei Kato, et al.
Molecular Cancer Therapeutics|August 5, 2020
High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse CancersPaul Riviere, Aaron M Goodman, Ryosuke Okamura, et al.
JNCI Cancer Spectrum|November 25, 2023
Characteristics of post hoc subgroup analyses of oncology clinical trials: a systematic reviewJawad Alrawabdeh, Marah Alzu'bi, Muntaser Alzyoud, et al.
Transplantation and Cellular Therapy|October 16, 2021
Assessing CAR T-Cell Therapy Response Using Genome-Wide Sequencing of Cell-Free DNA in Patients With B-Cell LymphomasAaron M Goodman, Kimberly A Holden, Ah-Reum Jeong, et al.
Molecular Cancer Therapeutics|September 1, 2021
Genome-wide Sequencing of Cell-free DNA Enables Detection of Copy-number Alterations in Patients with Cancer Where Tissue Biopsy is Not FeasibleTaylor J Jensen, Aaron M Goodman, Christopher K Ellison, et al.
Pageof 8

Showing results (61-70 of 79) with videos related to

Sort By:
Pageof 8
Blood Cancer Journal|November 15, 2022
Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015-2020Oliver Van Oekelen, Nicole Birrer, William Wesson, et al.
JAMA Oncology|June 15, 2018
Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid TumorsAaron M Goodman, David Piccioni, Shumei Kato, et al.
Blood Advances|March 1, 2023
Successful treatment of non-Langerhans cell histiocytosis with the MEK inhibitor trametinib: a multicenter analysisAshley Aaroe, Razelle Kurzrock, Gaurav Goyal, et al.
JAMA Internal Medicine|April 28, 2023
Comparing Physician and Artificial Intelligence Chatbot Responses to Patient Questions Posted to a Public Social Media ForumJohn W Ayers, Adam Poliak, Mark Dredze, et al.
Journal of Cancer Policy|December 7, 2023
Use of subjective minimizing language at hematology and oncology conferences: A systematic reviewAbdel-Azez Abusamak, Mohammad Abusamak, Mohammed Al-Abbadi, et al.
Molecular Cancer Therapeutics|December 8, 2018
Genome-Wide Sequencing of Cell-Free DNA Identifies Copy-Number Alterations That Can Be Used for Monitoring Response to Immunotherapy in Cancer PatientsTaylor J Jensen, Aaron M Goodman, Shumei Kato, et al.
Molecular Cancer Therapeutics|August 5, 2020
High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse CancersPaul Riviere, Aaron M Goodman, Ryosuke Okamura, et al.
JNCI Cancer Spectrum|November 25, 2023
Characteristics of post hoc subgroup analyses of oncology clinical trials: a systematic reviewJawad Alrawabdeh, Marah Alzu'bi, Muntaser Alzyoud, et al.
Transplantation and Cellular Therapy|October 16, 2021
Assessing CAR T-Cell Therapy Response Using Genome-Wide Sequencing of Cell-Free DNA in Patients With B-Cell LymphomasAaron M Goodman, Kimberly A Holden, Ah-Reum Jeong, et al.
Molecular Cancer Therapeutics|September 1, 2021
Genome-wide Sequencing of Cell-free DNA Enables Detection of Copy-number Alterations in Patients with Cancer Where Tissue Biopsy is Not FeasibleTaylor J Jensen, Aaron M Goodman, Christopher K Ellison, et al.
Pageof 8